<DOC>
	<DOCNO>NCT02579434</DOCNO>
	<brief_summary>The study objective evaluate validate endogenous marker assessment CYP3A activity Korean healthy subject use metabolomics . In part 1 , total 75 healthy subject ( male female ) enrol . In part 2 , total 25 healthy female subject age 20-45 year enrol . In part A B , subject administer midazolam I.V . 1 mg .</brief_summary>
	<brief_title>Evaluation Validation Endogenous Markers Assessment CYP3A Activity Korean Healthy Subjects Using Metabolomics</brief_title>
	<detailed_description />
	<mesh_term>Midazolam</mesh_term>
	<criteria>Age : Between 20 80 year age , inclusive Weight : Between 45 95 kg , within 17 28 Body Mass Index Subject agree contraception study Subject reliable willing make available study period , willing follow study protocol , give write informed consent voluntarily History hypersensitive reaction medication ( midazolam , ketoconazole , rifampicin ) History significant clinical illness need medical caution , include cardiovascular , immunologic , hematologic , neuropsychiatric , respiratory , gastrointestinal , hepatic , renal disease chronic disease history evidence drug abuse A subject whose lab test result abnormal A subject whose systolic blood pressure 140 mmHg 90 mmHg diastolic blood pressure 100 mmHg 50 mmHg Presence history drug abuse positive result urine drug screen test Blood donation 2 month apheresis 1 month study Use prescriptive medication Use alcohol 21 units/weeks Smoker smoke 10 cigarette per day Participation clinical trial drug within 60 day prior participation study Use grapefruit juice within 1 week first dose Use caffeine drink within 3 day first dose Subject pregnant breastfeeding Judged inappropriate study investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>CYP3A</keyword>
</DOC>